Clinical trialPhase 2Completed
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- May 2015
- Expected end
- March 2017
- Enrollment
- 77 participants
- Sites
- 1
- Primary outcomes
- Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.
- Sponsor
- Industry
- Results posted
- 2019-10-01
- Last update
- 1 October 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. [Every 12 weeks for up to 2 years.]. Count Of Participants, Participants. Arm 1 - Acalabrutinib Monotherapy (n=29): 0; Arm 2- Acalabrutinib+Pembrolizumab (n=27): 3.
Papers 1
- Registry-listed results paperRandomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patient… DOI 10.1136/jitc-2020-000587↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.